Screening

The Shield blood test is approved for primary CRC screening in adults 45 years and older at average risk for the disease.

Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.

Following audience polls, the panelists provide clinical insights into their screening practices for patients with type 1 diabetes, highlighting key antibodies they screen for.

The panel outlines the stages of type 1 diabetes, focusing on the importance of early intervention to prevent complications of the disease.

A blood test had a diagnostic accuracy of 91% compared with 61% accuracy by primary care clinicians and 73% by dementia specialists, according to new research.

The PATHFINDER 2 and HMS-Galleri trials are proceeding as planned with more than 175 000 participants from diverse backgrounds enrolled across both.

Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.

Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.

DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Your daily dose of the clinical news you may have missed.

In average-risk individuals, the at-home ColoSense test demonstrated 93% sensitivity for detecting CRC and 45% sensitivity for detecting advanced adenomas.

New research suggests the interval "could potentially be extended" without significant harms and could reduce unnecessary invasive procedures. , ie, missed early detection and CRC-specific mortality.

The USPSTF decision to reduce age of initiation is based on increasing rates of breast cancer in younger women; the group vows more research on higher mortality for Black women.

Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.

Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.

Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.

The CDC update recommends ending screening strategies that require multiple clinic visits for sample collection, favoring 1 visit and automatic HCV RNA testing.

The CAPTURE tool was able to identify 50% of primary care patients with COPD who could immediately benefit from treatment; experts say, it's a start.